Citadel Advisors
IPSC icon

Citadel Advisors’s Century Therapeutics IPSC Stock Holding History

Citadel Advisors’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,500
Closed -$1.51K – 15003
2024
Q4 		$1.51K Sell
1,500
-8,700
-85% -$11.8K ﹤0.01% 14179
2024
Q3 		$17.4K Buy
10,200
+9,900
+3,300% +$19.4K ﹤0.01% 12888
2024
Q2 		$765 Hold
300
– – ﹤0.01% 13921
2024
Q1 		$1.25K Sell
300
-100
-25% -$423 ﹤0.01% 14154
2023
Q4 		$1.33K Sell
400
-1,300
-76% -$2.37K ﹤0.01% 13846
2023
Q3 		$3.4K Buy
1,700
+1,600
+1,600% +$4.26K ﹤0.01% 13589
2023
Q2 		$316 Sell
100
-2,000
-95% -$6.45K ﹤0.01% 14152
2023
Q1 		$7.29K Sell
2,100
-200
-9% -$878 ﹤0.01% 13742
2022
Q4 		$11.8K Buy
+2,300
New +$21.7K ﹤0.01% 13553

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Citadel Advisors's IPSC Position: Q1 2026 in Review

Citadel Advisors sold out of Century Therapeutics (IPSC) in Q1 2026, closing a stake of 319,457 shares — an estimated $672K sold.

Citadel Advisors first reported a position in IPSC in Q3 2021 and held it in 16 quarters. The position peaked at $673K in Q4 2022. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

  • Citadel Advisors reported no remaining Century Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 319,457 Century Therapeutics shares in Q1 2026, an estimated $672K.
  • Citadel Advisors first reported a position in Century Therapeutics in Q3 2021 and held it in 16 quarters.
  • Citadel Advisors's Century Therapeutics position peaked at $673K in Q4 2022.
  • 72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.